{"id":2243,"date":"2025-12-03T09:15:31","date_gmt":"2025-12-03T08:15:31","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=2243"},"modified":"2025-12-03T09:04:24","modified_gmt":"2025-12-03T08:04:24","slug":"dextech-medicals-myeloma-study-odx-mm-001-dose-group-2-and-dose-group-3","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/dextech-medicals-myeloma-study-odx-mm-001-dose-group-2-and-dose-group-3\/","title":{"rendered":"DexTech Medical’s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3"},"content":{"rendered":"

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg\/kg body weight, 6mg\/kg, and 9mg\/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology\/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS.\u00a0 Adult myeloma patients with progressive, treatment-resistant,<\/em> disease, who have previously received 1\u20135 prior lines of treatment are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response.<\/p>\n

The last patient in dose group 2 (6mg\/kg) is expected to be finished at week 50 (7 doses). After 6 doses, the patient has still maintained their achieved stable disease, i.e. the progression verified prior to the start of treatment has stopped. The other 3 patients in dose group 2 have, after completion of ODX treatment and the disease was stable, now returned to their progressive disease.<\/p>\n

The first patient in dose group 3 (9mg\/kg) has received 3 doses to date. Here, too, the progressive disease has turned into a stable one. A further 2 patients in dose group 3 have only recently started their ODX treatment.<\/p>\n

This means that so far, 9\/9 (100%) of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). The patients are followed as planned after completion of ODX treatment; this is to map when the disease progresses again. The disease-inhibiting effect persists in some cases even after postponed ODX treatment, at most up to six months.<\/p>\n

“Overall, the results are remarkable and far better than we dared to hope for. The fact that the disease-inhibiting effect persists even after the end of ODX treatment is surprising. I believe that the results will arouse interest in ODX for the indication of multiple myeloma, in addition with the absence of serious side effects,” says CEO Anders R Holmberg.<\/em><\/p>\n

\u00a0<\/em>For more information about DexTech, please contact:<\/strong><\/p>\n

G\u00f6sta Lundgren \u2013 CFO<\/p>\n

DexTech Medical AB<\/p>\n

Phone: +46 (0) 707104788<\/p>\n

E-mail: gosta.lundgren@dextechmedical.com<\/p>\n

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 3, 2025.<\/em><\/p>\n

251203 – PR – DexTech Medical’s Myeloma Study, Dose Group 2 and 3<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2243","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"\nDexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech<\/title>\n<meta name=\"description\" content=\"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech\" \/>\n<meta property=\"og:description\" content=\"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T08:15:31+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\",\"url\":\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\",\"name\":\"DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2025-12-03T08:15:31+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DexTech Medical’s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech","description":"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/","og_locale":"en_US","og_type":"article","og_title":"DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech","og_description":"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2","og_url":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/","og_site_name":"DexTech","article_published_time":"2025-12-03T08:15:31+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/","url":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/","name":"DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2025-12-03T08:15:31+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"DexTech Medical’s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=2243"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2243\/revisions"}],"predecessor-version":[{"id":2246,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2243\/revisions\/2246"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=2243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=2243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=2243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}